SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that the U.S. Securities and Exchange Commission (SEC) has declared effective Inovio’s registration statement on Form S-4 related to Inovio’s pending merger transaction with VGX Pharmaceuticals Inc., a Blue Bell, Pennsylvania-based company focused on the discovery and development of DNA vaccines. Inovio and VGX are mailing the joint proxy statement/prospectus included in the registration statement to their respective shareholders, including a notice of each company’s respective special meeting of stockholders to be held on May 29, 2009.
